EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H’28 ...

If you receive JavaScript required to sign in error message when using Skype, OneDrive, Teams or any other program, you need to turn on or enable JavaScript in your ...

Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing ...

Keep the news in the Wayback Machine. Sign Fight for the Future's letter. Please Don't Scroll Past This Can you chip in? The Internet Archive partners with libraries, archives, and institutions across ...

At the same time, VIS-101 is also an important driver, and I apologise for now focusing on it too much. It provides a second leg to the story here, with a Phase 2b initiation expected sometime in 2H26 ...